Roche removed vixarelimab, an anti‑OSMRβ antibody acquired via its 2022 transaction with Kiniksa, from its Phase‑2 fibrosis pipeline after an interim futility analysis concluded the study was unlikely to meet efficacy endpoints. The decision follows Genentech’s internal review and a separate trimming of early‑stage antibody programs, including an anti‑VEGF/Ang‑2 candidate slated for ocular delivery. Roche said no new safety signals were identified but expressed disappointment in the lack of efficacy. The write‑downs highlight the risk of late‑stage failures and the strategic need for rigorous go/no‑go decision frameworks; Roche reiterated commitment to other platforms such as its Port Delivery System for retinal therapies even as it phases out underperforming assets.